⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ENTX News
Entera Bio Ltd. Ordinary Shares
Form 8-K
sec.gov
ENTX
ENTXW
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
globenewswire.com
ENTX
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
ENTX
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
globenewswire.com
ENTX
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
globenewswire.com
ENTX
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
globenewswire.com
ENTX
OPK
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
globenewswire.com
ENTX
Oral Protein and Peptides Market to Hit Valuation of US$ 47.33 Billion By 2035 | Astute Analytica
globenewswire.com
VKTX
LLY
NVO
MRK
FSK
TSN
KDP
PEP
MNDO
THG
ENTX
RANI
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
globenewswire.com
ENTX
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
globenewswire.com
ENTX